TSUMURA Top
ABOUT KAMPO
Kampo medicine has been highly expected more and more in the modern medicine
It has developed in its own way by adapting to the climate and culture of Japan and the constitution of the Japanese people, and has become a traditional Japanese medicine.
AT A GLANCE
Creating new value through innovations in Kampo
We will strive to achieve sustainable growth for the Group and increase our corporate value
Founded
130
years ago
(in 1893)
(in 1893)
Number of employees
(consolidated)
4,032
people
Number of our prescription formulations
129
of
total 148
total 148
Net sales
As of March 31, 2023
140.0
billion yen
China Sales
As of March 31, 2023
15.3
billion yen
Domestic market share ※
Kampo formulation for prescription
83.2
%
※Copyright © 2023 IQVIA. Estimated based on "JPM Mar.2023 MAT." Reprinted with permission
PRODUCT & QUALITY
Creating diversified value through the business of Kampo and raw materials
To ensure a stable supply of high quality Kampo Products
NEWS ROOM
-
2023.11.13 News ReleaseNotice Concerning Revision of Basic Capital Management Policy and Shareholder Return Policy and Revision of Dividends Projection (Dividend Increase)
-
2023.11.10 IR NewsSecond Quarter Business Results for Fiscal Year 2023（Script with Q&A)
-
2023.11.10 IR NewsSecond Quarter Business Results for Fiscal Year 2023（Presentation）
-
2023.11.07 IR NewsConsolidated Financial Results for the Second Quarter of the Term Ending March 31, 2024 (Under Japanese GAAP)
-
2023.11.07 IR NewsSupplementary Materials The Second Quarter of the Term Ending March 31, 2024
-
2023.11.01 News ReleaseTsumura Announces Revision of Earnings Forecast
-
2023.03.01TSUMURA USA, INC. Website has opened
-
2022.04.14Sustainability Vision & Long-Term Management Vision Presentation(with note)
-
2022.04.14Sustainability Vision & Long-Term Management Vision Presentation(Q&A Summary)
-
2022.04.01The Tsumura Group Sets Its Medium- to Long-Term Environmental Targets
-
2022.04.01Tsumura Human Rights Policy Established
-
2022.04.01Tsumura Procurement Policy Established
-
2023.11.13Notice Concerning Revision of Basic Capital Management Policy and Shareholder Return Policy and Revision of Dividends Projection (Dividend Increase)
-
2023.11.01Tsumura Announces Revision of Earnings Forecast
-
2023.04.20Tsumura Announces Conclusion of Agreement Regarding Acquisition of Equity Interest in Shaanxi Unisplendour Life Care Pharmaceutical Co., Ltd. by Ping An Tsumura Inc.
-
2023.03.23Tsumura Announces Introduction of Trust-type Stock Delivery System for Employees
-
2022.09.12Tsumura Announces Signing of Letter of Intent Concerning Establishment of Joint Venture with Jianmin Pharmaceutical Group Co., Ltd.
-
2022.09.12Tsumura Announces Establishment of PINGAN TSUMURA TRADITIONAL CHINESE MEDICINE TECHNOLOGY CO., LTD.
-
2023.11.10Second Quarter Business Results for Fiscal Year 2023（Script with Q&A)
-
2023.11.10Second Quarter Business Results for Fiscal Year 2023（Presentation）
-
2023.11.07Consolidated Financial Results for the Second Quarter of the Term Ending March 31, 2024 (Under Japanese GAAP)
-
2023.11.07Supplementary Materials The Second Quarter of the Term Ending March 31, 2024
-
2023.08.21First Quarter Business Results for Fiscal Year 2023（Conference Call）Q&A
-
2023.08.10First Quarter Business Results for Fiscal Year 2023（Conference Call with script）
